Some FAK inhibitors have moved into phase II clinical trials as part of combinatorial treatments with either other pharmacological inhibitors or blocking antibodies in multiple solid tumors, including pancreatic cancer and non-small-cell lung carcinoma (clinical trial identifiers: NCT02758587 and NCT02546531, respectively). The gene discussed is PTK2; the disease is familial pancreatic carcinoma.